The development of new rubella diagnostic tools is essential for rubella management and control. Protheragen is at the forefront of developing innovative diagnostic tools that will enhance rubella control due to our spearhead programs in rubella's advanced research. As your dependable partner in abrangendom rubella diagnostic evaluation, we offer you distinct support to meet your research needs.
Overview of Rubella
Rubella is an infectious viral disorder including symptoms of a rash, mild fever, sore throat, swollen lymph nodes, and tiredness. It can also result in severe impairments to a newborn's hearing and vision, as well as neurological concerns and heart abnormalities. Rubella is transmitted through the rubella virus which can either be passed on from the mother to the child or from one person to another through respiratory droplets. Although rubella is vaccine preventable, it still remains a global health challenge.
Fig. 1 Effects of antenatal rubella infection on the brain. (Al-Beltagi, Mohammed, et al., 2023)
Diagnostic Biomarkers for Rubella
Rubella is far more difficult to diagnose and can have a greater effect on susceptible people such as pregnant women and newborns. The identification of specific diagnostic biomarkers for rubella would be useful in the optimization of rubella detection, treatment as well as the development of rubella-specific diagnostic tools.
Rubella Virus-Specific Antibodies
Found out that rubella virus antibodies made by the immune system could act as a useful biomarker for the identification of ongoing or previous rubella infections. Antibody tests, such as IgM and IgG assays, can confirm rubella due to recent or past exposure to the disease.
Rubella Virus RNA
The detection of rubella virus RNA in blood or nasopharyngeal swab specimens can be employed as a direct marker of active infection and molecular tools such as polymerase chain reaction can be used to identify the presence of viral RNA which is a reliable means of diagnosing rubella.
IVD Kits for Rubella
Rubella in vitro diagnostics (IVDs) offer precise and timely information crucial for efficient care, disease monitoring, and public health initiatives. As per the report, the rubella IVD market size is projected to be $1.46 billion in 2025 and is anticipated to surpass $1.89 billion by 2030, exhibiting a compound annual growth rate of 5.23% over the forecast period (2025-2030). Various IVD kits for rubella constitute a significant portion of this market.
Rubella IgG/IgM Rapid Test Kit
The kit uses a lateral flow immunoassay for the semi-quantitative detection and differentiation of rubella virus antibodies (IgG and IgM) in human serum, plasma or whole blood.
Rubella Virus RNA Detection Kit
Typically, the kit utilizes qPCR for rapid and precise identification of the rubella virus RNA, aiding in the diagnosis, therapeutic, and public health control of individuals infected with the virus.
Our Services
Protheragen specializes in the creation of personalized in vitro diagnostic (IVD) solutions for infectious diseases like rubella, and is working on improving the diagnostic precision with the aids of developed antigen, antibody, and RNA test kits. In particular, our main contribution lies in the development of rapid test kits contributing to the effective diagnosis of rubella virus during viral infections.
Featured IVD Development Services for Rubella
- Rubella Virus RNA Sequence Development Service
- Rubella Virus Primer and Probe Design Service
- Rubella Virus Antigen Development Service
- Rubella Virus Antibody Development Service
- Rubella Virus Assay Development Service
- Quality Control Product Development Service
IVD Product Development Services
To tailor the therapies of rubella, Protheragen provides companion diagnostic development services aimed at identifying the optimal therapeutic strategies for affected individuals. This encompasses the analysis of particular biomarkers or genetic markers associated with the illness in order to identify the best intervention.
If our services have peaked your interest, don't hesitate to get in touch with us so you can receive a detailed quote of the service.
Reference
- Al-Beltagi, Mohammed, et al. "Viruses and autism: A Bi-mutual cause and effect." World journal of virology 12.3 (2023): 172.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
